Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03440866
Other study ID # 2-17 EMC
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2018
Est. completion date December 30, 2023

Study information

Verified date November 2022
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Medical termination of pregnancy is a common and safe alternative to surgical termination of pregnancy(8). The current protocol in the investigators unit includes oral administration of Mifepristone 600 mg and oral Misoprostol 400 mcg in a time interval of 48 hours. There is little data to compare the efficacy of concomitant administration of both drugs and different time intervals. This study evaluates the success rate and side effects of medical termination of pregnancy while both drugs are administrated concomitantly in comparison to interval of 48 hours between the drugs.


Description:

Medical termination of pregnancy is a common and safe alternative to surgical termination of pregnancy(8). According to the original protocol ,the administration of oral Mifepristone 600 mg is followed by oral Misoprostol 400 mcg in an interval of 36 to 48 hours. Shortening this time interval may convince patients to avoid surgical termination of pregnancy, enhance patient's compliance to treatment and even be more economically. The current protocol in the investigators unit includes oral administration of Mifepristone 600 mg and oral Misoprostol 400 mcg in a time interval of 48 hours. The patients are recommended to have an ultrasound examination after 2 to 3 weeks. There is little data to compare the efficacy of concomitant administration of both drugs according to the dosage of this protocol and different time intervals. This study evaluates the success rate and side effects of medical termination of pregnancy while both drugs are administrated concomitantly in comparison to interval of 48 hours between the drugs. Participants in the study group will be given both drugs at the same time while participants in the control group will be given Mifepristone and Misoprostol in an interval of 48 hours. The investigators hypothesis is that administration of both drugs concomitantly will not change significantly the success rate of the procedure and will not enhance the side effects.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 250
Est. completion date December 30, 2023
Est. primary completion date December 30, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - intrauterine singleton pregnancy of less than 49 days, reassured by ultrasound examination - patient who desire to terminate their pregnancy and have approval of the committee for termination of pregnancy - patient who gave their consent to have a surgical abortion eventual if needed Exclusion Criteria: - contraindication to Mifepristone or Misoprostol - suspected ectopic pregnancy - systemic treatment with steroids - adrenal insufficiency - heart and blood vessels disease - coagulopathy or use of anti-thrombotic agents - uncontrolled asthma - liver or kidney insufficiency - anorexia - intrauterine device - breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Administration of drugs concomitantly.
Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.

Locations

Country Name City State
Israel HaEmek medical center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

References & Publications (13)

Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA; MOD Study Trial Group. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004 May;103(5 Pt 1):851-9. doi: 10.1097/01.AOG.0000124271. — View Citation

Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA; Medical Abortion at the Same Time (MAST) Study Trial Group. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol. 2007 Apr;109(4):885-94. doi: 10.1097/01.AOG.0000258298.35143.d2. — View Citation

Creinin MD, Schwartz JL, Pymar HC, Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG. 2001 May;108(5):469-73. doi: 10.1111/j.1471-0528.2001.00117.x. — View Citation

Garg G, Takkar N, Sehgal A. Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. J Obstet Gynaecol India. 2015 Apr;65(2):111-6. doi: 10.1007/s13224-014-0605-5. Epub 2014 Oct 31. — View Citation

Goel A, Mittal S, Taneja BK, Singal N, Attri S. Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Arch Gynecol Obstet. 2011 Jun;283(6):1409-13. doi: 10.1007/s00404-011-1881-2. Ep — View Citation

McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod. 1993 Sep;8(9):1502-5. doi: 10.1093/oxfordjournals.humrep.a138287. — View Citation

Murthy AS, Creinin MD, Harwood B, Schreiber C. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception. 2005 May;71(5):333-6. doi: 10.1016/j.contraception.2004.10.006. — View Citation

Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception. 2006 Jul;74(1):42-4. doi: 10.1016/j.contraception.2006.03.014. Epub 2006 May 12. — View Citation

Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001 Aug;64(2):81-5. doi: 10.1016/s0010-7824(01)00229-3. — View Citation

Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BMJ. 1993 Aug 28;307(6903):532-7. doi: 10.1136/bmj.307.6903.532. — View Citation

von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, Tang OS, Fang AH, Wu SC, Kalmar L, Mittal S, Erdenetungalag R, Horga M, Pretnar-Darovec A, Kapamadzija A, Dickson K, Anh ND, Tai NV, Tuyet HT, Peregoudov A; WHO Research Group on Post-ovulatory — View Citation

Wedisinghe L, Elsandabesee D. Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. Contraception. 2010 Apr;81(4):269-74. doi: 10.1016/j.contraception.2009.09.007. Epub 2009 Oct 29. — View Citation

World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation; Special Programme of Research, Development and Research Training; World Health Organisation. Comparison of two doses of mifepristone in combination with misoprostol fo — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate of complete abortion Success rate of complete abortion without any other surgical intervention two weeks
Secondary Bleeding amount Assessment of bleeding amount and duration by the patient (maximum amount of pads per day) and Hemoglobin level before and two weeks after the procedure two weeks
Secondary Self reported pain intensity after two weeks Visual analogue scale pain severity with scale from 0 to 10, with score 10 representing the maximum level of pain during those two weeks. two weeks
Secondary patient's satisfaction Post operative women's satisfaction with scale from 0 to 10, with score 10 representing the maximum level of satisfaction. the patient will be asked if she will select this method next time if necessary two weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01639989 - Doppler Assesment of Blood Flow in the Spiral Arteries N/A
Recruiting NCT06002412 - Quality Control of Ultrasound Images During Early Pregnancy Via AI
Completed NCT03258385 - Vitamin B12 Supplementation to Improve B12 Status and Child Development N/A
Completed NCT04152278 - Chlamydia Tracomatis and Other Lower Genital Tract Infections Among Women With Unexplained Early Miscarriage
Completed NCT03161873 - Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)
Completed NCT02979834 - When Will I Feel The First Movements of My Baby? N/A
Terminated NCT02847910 - ClinicaI Observation of Induced Abortion With Disposable Tissue Suction Tube N/A
Completed NCT04371991 - Kisspeptin Levels in Early Pregnancy
Active, not recruiting NCT05142020 - Biomarkers for Early Screening of Gestational Diabetes Mellitus
Recruiting NCT04717661 - A Diagnostic Test Study of Characteristic Sound Waves in Radial Artery of Early Pregnant Women
Completed NCT05484869 - Very Advanced Maternal Aged Pregnants and Early Adolescent Pregnant Women
Recruiting NCT04738370 - Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy
Completed NCT06228118 - Clinical Trail of the Lay User Study and Method Comparison Study of Human Chorionic Gonadotropin (HCG) Test System
Completed NCT06228131 - Detection of hCG in Early Pregnancy Clinical Samples
Active, not recruiting NCT04388605 - Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic
Completed NCT00340782 - Influence of Social and Environmental Factors on Women's Reproductive Function in a Maya Community of Guatemala N/A